
What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
Second Individual Cured of HIV Reveals Identity
A year after being only the second person to be cured of HIV, Adam Castillejo, known as the “London Patient,” revealed his identity stating, “I want to be an ambassador of hope.” According to
Bristol Myers Squibb’s MM Combo Therapy Fails to Meet Primary End Point
FDA Accepts BLA for Mylan, Biocon Proposed Biosimilar Bevacizumab
Bristol Myers Squibb Co (BMS) announced today that its combination therapy for multiple myeloma (MM) failed its primary end point in the phase 3 ELOQUENT-1 trial of improving progression-free survival (PFS) in newly diagnosed patients, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.